<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2812223045
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EMDOX 100 mg/5 ml DS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFPODOXIME
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pharma International Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pharma International Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cefpodoxime is an antibiotic used to kill bacteria, which cause infection in your<br />body. It belongs to a group of antibiotics called cephalosporins.<br />Your doctor has prescribed <strong>Emdox&reg; </strong>Oral Suspension because you have one (or<br />more) of the following types of infection:<br />&bull;&thinsp;tonsilitis<br />&bull;&thinsp;sinusitis<br />&bull;&thinsp;otitis media<br />&bull;&thinsp;pneumonia</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&thinsp;If you are allergic (hypersensitive) to cefpodoxime or other cephalosporins or any<br />of the other ingredients of this medicine.<br />&bull;&thinsp;If you have had a severe allergic reaction to particular antibiotics (penicillins,<br />monobactams and carbapenems) as you may also be allergic to cefpodoxime.<br />Tell your doctor before you start on <strong>Emdox&reg;</strong> Oral Suspension if you think that this<br />applies to you. You must not be given<strong> Emdox&reg;</strong> Oral Suspension.<br /><strong>Take special care with Emdox&reg; Oral Suspension<br />Talk to your doctor or pharmacist before taking Emdox&reg; Oral Suspension</strong><br />&bull;&thinsp;If you have ever been told that your kidneys do not work very well. Also, if you<br />are having any sort of treatment (like dialysis) for kidney failure. You may take<br /><strong>Emdox&reg;</strong> Oral Suspension but you may need a lower dose.<br />&bull;&thinsp;If you have ever had inflammation of your bowel, called colitis or any other severe<br />disease affecting your gut.<br />&bull;&thinsp;This medicine can alter the results of some blood tests (such as cross-matching<br />blood and the coomb&rsquo;s test). It is important to tell the doctor that you are taking this<br />medicine if you have to have any of these tests.<br />&bull;&thinsp;This medicine can also alter the results of urine tests for sugar (such as Benedict&rsquo;s<br />or Fehling&rsquo;s tests). If you have diabetes and routinely test your urine, tell your<br />doctor. This is because other tests may have to be used to monitor your diabetes<br />while you are having this medicine.<br /><strong>Taking other medicines</strong><br />Please tell to your doctor or pharmacist if you are taking or have recently taken any<br />other medicines, including medicines obtained without a prescription.<br />This medicine can be affected by other medicines that are removed by the kidneys.<br />This is especially if these other medicines also affect how well kidneys work. There<br />are many medicines that can do this, so should check with your doctor or pharmacist<br />before taking this medicine.<br />In particular, tell your doctor or pharmacist if you are taking:<br />&bull; antacids (used to treat indigestion)<br />&bull; anti-ulcer agents (used to treat ulcer) such as ranitidine or cimetidine<br />&bull; diuretics (used to increase urine flow)<br />&bull; aminoglycoside antibiotics used to treat infections<br />&bull; probenecid (used in the treatment of gout)<br />&bull; anti-coagulants e.g. warfarin<br />Antacids and anti-ulcer treatments (such as ranitidine and cimetidine) should be<br />taken 2-3 hours after taking store <strong>Emdox&reg;</strong> Oral Suspension. Your doctor knows<br />about these and will alter the treatment if considered necessary.<br />If you require any tests (blood, urine or diagnostic), whilst taking this medicine,<br />please ensure that your doctor knows that you are taking <strong>Emdox&reg;</strong> Oral Suspension.<br /><strong>Emdox&reg; Oral Suspension contains sucrose.</strong><br />If you have been told by your doctor that you have an intolerance to some sugars<br />contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Emdox&reg; Oral Suspension exactly as your doctor has told you. Check<br />with your doctor or pharmacist, if you are not sure.<br /><strong>Instructions for Reconstitution</strong><br />To prepare the suspension first shake the bottle to loosen granules.<br />Add water up to about half of the 100 ml ring mark and shake vigorously. Further<br />add water up to the 100 ml ring mark of the bottle and shake vigorously to obtain an<br />evenly dispersed suspension.<br />The recommended mean dosage for children (up to 11 years) is 8 mg/kg/day<br />administered in two divided doses at 12-hour intervals.<br />The dose to be taken is indicated on the measuring spoon. The graduations<br />correspond to the child&rsquo;s weight in kg from 5 kg to 25 kg with intermittent<br />graduations of 1 kg each.<br />The dose to be taken is read directly from the spoon. For example, if your child<br />weighs 12 kg, the spoon is filled to the 2nd graduation after 10 kg graduation mark.<br />The measuring spoon is only adequate for this oral suspension.<br />The following table provides dosage regimen for children as per the bodyweight<br />graduations provided on the measuring spoon:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Body weight in kg</strong></p></td><td style="vertical-align:top"><p><strong>Emdox&reg; Oral Suspension dose in mg to</strong></p><p><strong>be used twice daily</strong></p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>100</p></td></tr></tbody></table><p><br />Children who weigh at least 25 kg can take 12.5 ml suspension twice daily or<br />alternatively 100 mg film-coated tablet twice daily.<br /><strong>Children with kidney problems:</strong><br />Depending on how serious the kidney problems are, you may need to take Emdox&reg;<br />Oral Suspension less often, e.g. only once a day or every other day. Your doctor will<br />decide how much you need to take.<br />It is important that you take your medicine at the right times of day.<br /><strong>How to take:</strong><br />It is important that you take your medicine at the right times of day. This medicine<br />may be taken with or without food.<br /><strong>If you take more Emdox&reg; Oral Suspension than you should</strong><br />If you accidentally take too much medicine, contact your doctor or pharmacist who<br />will recommend what action you should take.<br /><strong>If you forget to take Emdox&reg; Oral Suspension</strong><br />If you do forget to take a dose of your medicine at the correct time, you should<br />take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. Just<br />take the next dose at the correct time. Carry on as before.<br /><strong>If you stop taking Emdox&reg; Oral Suspension</strong><br />Keep taking your medicine until your doctor has told you to stop. Do not stop<br />taking it just because you feel better. If you stop taking the medicine, your<br />condition may reoccur or get worse.<br />If you have any further questions on the use of this medicine, ask your doctor<br />or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Cefpodoxime can cause side effects, although not<br />everybody gets them. The side effects are listed by frequency.<br /><strong>Conditions you need to look out for</strong><br />The following serious side effects have occurred in a small number of people<br />but their exact frequency is unknown:<br />&bull;&thinsp;severe allergic reaction. Signs include raised and itchy rash, swelling,<br />sometimes of the face or mouth causing difficulty in breathing.<br />&bull;&thinsp;Skin rash, which may blister, and looks like small targets (central dark spot<br />surrounded by a paler area, with a dark ring around the edge).<br />&bull;&thinsp;A widespread rash with blisters and peeling skin. (These may be signs of<br />Stevens-Johnson syndrome or toxic epidermal necrolysis).<br /><strong>All of these reactions need urgent medical attention. If you think you<br />are having any of these types of reaction, stop taking this medicine and<br />contact your doctor or your nearest hospital accident and emergency department.<br />Common side effects (affects more than 1 person in 100 but less than 1 in 10):</strong><br />&bull;&thinsp;Stomach problems: Bloating, nausea, vomiting, stomach pain, flatulence (wind) and diarrhea.<br />&bull;&thinsp;Loss of appetite<br />If you have severe diarrhea or if you see blood in your diarrhea you should<br />stop taking this medicine and talk to your doctor immediately.<br /><strong>Uncommon side effects (affects more than 1 person in 1,000 but less than 1 in 100):</strong><br />&bull;&thinsp;Hypersensitivity reactions (These are skin rashes that are less severe allergic<br />reactions than mentioned above, lumpy rash (hives), itching)<br />&bull;&thinsp;Headache<br />&bull;&thinsp;Pins and needles<br />&bull;&thinsp;Dizziness<br />&bull;&thinsp;Ringing in the ears<br />&bull;&thinsp;Weakness and a feeling of generally being unwell.<br />Rare side effects (affects more than 1 person in 10,000 but less than 1 in 1,000):<br />&bull;&thinsp;Changes in blood tests that check how your liver is working<br />&bull;&thinsp;Anaemia<br />&bull;&thinsp;Drops in the numbers of blood cells (symptoms can include tiredness, new<br />infections and easy bruising or bleeding)<br />&bull;&thinsp;Increase in some types of white blood cells<br />&bull;&thinsp;Increase in the numbers of small cells that are needed for clotting of the blood.<br /><strong>Very rare side effects (affects less than 1 person in 10,000):</strong><br />&bull;&thinsp;Anaphylactic reactions (e.g. bronchospasms, purpura and edema of the face and extremities)<br />&bull;&thinsp;Worsening in the kidney function<br />&bull;&thinsp;Liver damage<br />&bull;&thinsp;Having a course of cefpodoxime can temporarily increase the chance that<br />you can get infections caused by other sorts of germs. For example, thrush may occur.<br />&bull;&thinsp;A type of anaemia that can be severe and is caused by red blood cells breaking up.<br /><strong>If any of the side effects gets serious, or if you notice any side effects not<br />listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight ofchildren.<br />Do not use <strong>Emdox&reg; </strong>Oral Suspension after the expiry date (EXP) which is<br />stated on the carton and label.<br />The expiry date refers to the last day of the month.<br /><strong>Emdox&reg;</strong> Oral Suspension: Store dry powder below 30oC.<br />After the powder has been mixed with water by the pharmacist, keep the<br />bottles of medicine in the refrigerator.<br />After being mixed with water, <strong>Emdox&reg; </strong>Oral Suspension can be used for 14<br />days. Any liquid remaining after 14 days should be disposed of properly.<br />Medicines should not be disposed of viawastewater or household waste.<br />Ask yourpharmacist how to dispose of medicines nolonger required. These<br />measures will helpto protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Each 5ml spoonful of liquid contains 100mg of the active substance<br />cefpodoxime proxetil<br />&bull; The other ingredients are Hydroxy propyl cellulose, microcrystalline<br />cellulose, maize starch, sucrose, citric acid, colloidal silicon dioxide,<br />simethicone emulsion, Microcrystalline cellulose and carboxymethyl<br />cellulose, sodium saccharin, xanthan gum, lemon powder flavor, vanilla<br />powder flavor.</p><p><br /><strong>What Emdox&reg; Oral Suspension looks like and content of the pack</strong><br />&nbsp;</p><p><strong>Emdox&reg;</strong> Oral Suspension 100mg/5ml are available in 50ml bottles and come<br />with a measuring spoon (10 ml) &amp; a Child resistant cap.<br />The bottle contains powder which has been mixed with water by your<br />pharmacist, to form a Lemon flavoured medicine ready for use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Emdox® Oral Suspension 100mg/5ml are available in 50ml bottles and come
with a measuring spoon (10 ml) & a Child resistant cap.
The bottle contains powder which has been mixed with water by your
pharmacist, to form a Lemon flavoured medicine ready for use.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong>PIC- Jordan<br /><strong>Pack by</strong>: Madinat Dawaa Pharmaceutical Industries-Jeddah- KSA<br /><strong>MAH is</strong>: Madinat Dawaa Pharmaceutical Industries-Jeddah- KSA<br />Tel: 00966126538171<br />Fax: 00966126358138<br />Mobile: 00966540640627<br />E-mail: madinet.aldawaa@gmail.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سيفبودوكسيم هو مضاد حيوي يستعمل للقضاء على البكتيريا، التي تسبب الالتهاب في الجسم.<br />وينتمي إلى مجموعة من المضادات الحيوية التي تعرف بالسيفالوسبورينات.<br />&nbsp;لقد قام طبيبك بوصف إيمدوكس&reg;&nbsp;معلق للشرب لأنك تعاني من واحد )أو أكثر( من الأنواع التالية<br />من الالتهابات:<br />&bull;التهاب اللوزتين.<br />&bull;التهاب الجيوب الأنفية.<br />&bull;التهاب الأذن الوسطى.<br />&bull;التهاب الرئتين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول إيمدوكس&reg; معلق للشرب في الحالات التالية:</strong><br />&bull;إذا كنت تعاني من تحسس (فرط التحسس) لسيفبودوكسيم أو لأي من المضادات الحيوية الأخرى<br />من مجموعة السيفالوسبورينات أو لأي من المكونات الأخرى في هذا الدواء.<br />&bull;إذا عانيت في السابق من تفاعل تحسسي حاد لمضادات حيوية معينة (البنسيلينات، مونوباكتام<br />وكاربابينيم) حيث قد تعاني أيضا من تحسس لسيفبودوكسيم.<br />أخبر طبيبك قبل بدء تناول <strong>إيمدوكس&reg; معلق للشرب&nbsp;</strong>إذا كنت تعتقد أن هذا ينطبق عليك. يجب عدم</p><p>إعطائك <strong>إيمدوكس&reg; معلق للشرب</strong><br /><strong>الاحتياطات الخاصة عند تناولإيمدوكس&reg; معلق للشرب</strong><br />معلق للشرب في الحالات التالية: &reg; تحدث مع طبيبك أو الصيدلي قبل تناول إيمدوكس<br />&bull;إذا أخبرت في السابق من قبل الطبيب أنك تعاني من قصور في وظيفة الكلى. أيضا، إذا كنت<br />تخضع لأي نوع من أنواع علاج قصور وظيفة الكلى )مثل الديلزة(. من الممكن أن تتناول<br />معلق للشرب لكن قد تحتاج جرعة أقل. &reg; إيمدوكس<br />&bull;إذا عانيت في السابق من التهاب في الأمعاء، يعرف بالتهاب القولون أو أي مرض آخر حاد<br />يؤثر على الأمعاء.<br />&bull;قد يغير هذا الدواء من نتائج بعض فحوصات الدم )مثل فحص مطابقة الدم و فحص كومب(. من<br />الضروري أن تخبر طبيبك أنك تتناول هذا الدواء إذا كنت ستخضع لأي من هذه الفحوصات.<br />&bull;قد يغير هذا الدواء أيضا من نتائج فحوصات البول المتعلقة بمستوى السكر )مثل فحص بينيديكت<br />أو فحص فهلينج( إذا كنت تعاني من داء السكري و تخضع لفحص دوري للبول، أخبر طبيبك.<br />هذا لأنه قد يكون من الضروري الخضوع لفحوصات أخرى لمراقبة داء السكري خلال فترة<br />تناولك هذا الدواء.<br /><strong>تناول أدوية أخرى</strong><br />الرجاء إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك<br />الأدوية التي يتم الحصول عليها بدون وصفة طبية.<br />قد تؤثرالأدوية الأخرى التي يتم التخلص منها عن طريق الكلى على طريقة عمل هذا الدواء،<br />وخصوصا إذا كانت هذه الأدوية الأخرى أيضا تؤثر على طريقة عمل الكلى. هناك العديد من<br />الأدوية التي قد تقوم بذلك، لذلك يجب التأكد من طبيبك أو الصيدلي قبل تناول هذا الدواء.<br />بشكل خاص، أخبر طبيبك أو الصيدلي إذا كنت تتناول أي مما يلي:<br />&bull;مضادات الحموضة (تستخدم لعلاج عسر الهضم).<br />&bull;الأدوية المضادة للقرحة (تستعمل لعلاج القرحة) مثل رانيتيدين أو سيميتيدين.<br />&bull;مدرات البول )تستخدم لزيادة تدفق )إخراج( البول(.<br />&bull;المضادات الحيوية من مجموعة أمينوجلايكوسايد التي تستعمل لعلاج الالتهابات.<br />&bull;بروبنيسيد )يستعمل لعلاج النقرس(.<br />&bull;مضادات التجلط مثل الوارفارين.<br />يجب تناول مضادات الحموضة والأدوية المضادة للقرحة (مثل رانيتيدين و سيميتيدين) بعد 2-3 ساعات من تناول&nbsp; <strong>إيمدوكس&reg; معلق للشرب</strong><br />إن طبيبك يعلم بذلك وسيقوم بتغيير العلاج إذا ادعت الحاجة.<br />إذا كنت بحاجة للقيام بأي فحوصات )مثل فحوصات الدم، البول أو الفحوصات التشخيصية(،<br />خلال فترة تناول هذا الدواء، الرجاء التأكد من أن طبيبك يعلم بأنك تتناول <strong>إيمدوكس&reg; معلق للشرب</strong><br /><strong>يحتوي إيمدوكس&reg; معلق للشرب</strong><strong> على السكروز</strong><br />إذا أخبرت من قبل الطبيب أنك لا تستطيع تحمل بعض أنواع السكريات، اتصل مع طبيبك قبل<br />تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول&nbsp;<strong>إيمدوكس&reg; </strong> معلق للشرب دائما كما أخبرك طبيبك تماما. يجب التأكد من طبيبك أو الصيدلي،&nbsp;<br />إذا لم تكن متأكدا.<br /><strong>تعليمات تحضير المعلق للشرب</strong><br />لتحضير المعلق قم أولا بهز الزجاجة لتتمكن الحبيبات العالقة على الجوانب من النزول.<br />قم بإضافة الماء ما يعادل تقريبا نص الكمية المطلوب إضافتها لتصل إلى الحلقة الموجودة على<br />الزجاجة التي تشير إلى 100 مل و قم برج الزجاجة بقوة. بعد ذلك قم بإضافة المزيد من الماء<br />لتصل إلى الحلقة الموجودة على الزجاجة التي تشير إلى 100 مل و قم برج الزجاجة بقوة<br />للحصول على معلق متجانس.<br />إن متوسط الجرعة الموصى بها للأطفال )لغاية 11 عام( تبلغ 8 ملغم/كغم/يوم يتم تناولها على<br />جرعتين منفصلتين على فترات تبلغ 12 ساعة.<br />يتم قياس الجرعة الواجب تناولها باستعمال ملعقة القياس المدرجة. إن التدريجات التي تعادل<br />وزن الطفل بالكيلوغرام تبدأ من 5 كغم إلى 25 كغم و وبين كل تدريج والآخر هناك تدريجات<br />تعادل 1 كغم.<br />يتم قراءة الجرعة الواجب تناولها مباشرة من الملعقة المدرجة. مثلا، إذا كان وزن طفلك يبلغ 12<br />كغم، يتم ملء الملعقة إلى التدريج الثاني بعد العلامة التي تعادل 10 كغم.<br />تعد الملعقة المدرجة هي الوحيدة المناسبة لتناول هذا المعلق. إن الجدول التالي يوضح نظام<br />الجرعة للأطفال حسب التدريجات التي تعادل وزن الجسم والمزودة على الملعقة المدرجة:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>وزن الجسم يالكيلو غرام</strong></p></td><td style="vertical-align:top"><p><strong>جرعة</strong><strong>إيمدوكس&reg; معلق للشرب</strong><strong> </strong><strong>بالملغم الواجب تناولها مرتين يوميا</strong></p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>20</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>40</p></td></tr><tr><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>60</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>100</p></td></tr></tbody></table><p>من الممكن أن يتناول الأطفال الذين تبلغ أوزانهم على الأقل 25 كغم جرعة 12.5 مل من المعلق<br />مرتين يوميا أو بدلا عن ذلك قرص من أقراص 200 ملغم مرتين يوميا.<br /><strong>الأطفال الذين يعانون من مشاكل في الكلى:</strong><br />اعتمادا على خطورة مشاكل الكلى، قد تحتاج تناول <strong>إيمدوكس&reg;</strong>&nbsp;معلق للشرب بتكرار أقل، مثلا<br />مرة واحدة يوميا أو كل يوم بعد يوم. سيقرر الطبيب الجرعة التي تحتاج لتناولها.<br />من الضروري تناول دوائك في الأوقات الصحيحة من اليوم.<br /><strong>كيفية استخدامه:</strong><br />من الضروري تناول دوائك في الأوقات الصحيحة من اليوم. من الممكن تناول هذا الدواء مع أو<br />بدون تناول الطعام.<br /><strong>&nbsp;إذا قمت بتناول&nbsp;إيمدوكس&reg;&nbsp;معلق للشرب أكثر مما يجب&nbsp;</strong><br />إذا تناولت أكثر مما يجب من الدواء عن طريق الخطأ، اتصل مع طبيبك أو الصيدلي الذيسيوصيك باتخاذ الإجراء المناسب.<br /><strong>إذا نسيت تناول جرعة إيمدوكس&reg; معلق للشرب</strong><br />إذا نسيت تناول جرعة من دوائك في الوقت المناسب، يجب تناولها في أقرب وقت ممكن. لكن، إذا<br />اقترب موعد الجرعة التالية، اترك الجرعة التي نسيتها. لا تتناول جرعة مضاعفة لتعويض الجرعة<br />التي نسيتها. فقط تناول الجرعة التالية في الوقت المناسب. واستمر كما في السابق.<br />&nbsp;<strong>إذا توقفت عن تناو ل إيمدوكس&reg;&nbsp;معلق للشرب</strong><br />استمر في تناول دوائك إلى أن يخبرك طبيبك بالتوقف عن ذلك. لا تتوقف عن تناوله فقط لأنك<br />تشعر بتحسن. إذا توقفت عن تناول الدواء، قد يعود الالتهاب مرة أخرى أو قد يزداد&nbsp;&nbsp;سوءا.<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.&nbsp; &nbsp; &nbsp; &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يسبب سيفبودوكسيم آثار جانبية، على الرغم من عدم حدوثها لدى الجميع. تم<br />تصنيف الآثار الجانبية حسب التكرار.<br /><strong>حالات يجب الانتباه لحدوثها</strong><br />إن الآثار الجانبية الخطيرة التالية حصلت عند عدد قليل من الأشخاص لكن تكرار حدوثها الدقيق<br />غير معروف:<br />&bull;تفاعل تحسسي حاد. تشمل العلامات طفح بارز على سطح الجلد ويسبب الحكة، تورم، أحيانا في<br />الوجه أو الفم مما يسبب صعوبة في التنفس.<br />&bull;طفح جلدي، الذي قد يسبب تنفط، ويظهر كبقع صغيرة (بقع ذات مركز داكن محاط بمنطقة أكثر<br />شحوبا محاطة بحلقة داكنة على الأطراف).<br />&bull;طفح واسع الانتشار مصحوبا بتنفط و تقشر الجلد.(قد تكون هذه علامات متلازمة ستيفن جونسون<br />أو تحلل نخري سام في البشرة).<br /><strong>تحتاج جميع هذه التفاعلات عناية طبية طارئة. إذا كنت تعتقد بأنك تعاني من أحد أنواع هذه<br />التفاعلات، توقف عن تناول هذا الدواء واتصل مع طبيبك أو قسم الطوارئ والحوادث في أقرب<br />مستشفى.<br />آثار جانبية شائعة (تؤثر على أكثر من 1 من كل 100 شخص لكن أقل من 1 من كل 10<br />أشخاص):</strong><br />&bull;مشاكل في المعدة: انتفاخ البطن، الشعور بالغثيان، قيء، ألم في المعدة، نفخة )ريح( وإسهال.<br />&bull;فقدان الشهية.<br />إذا كنت تعاني من إسهال حاد أو إذا لاحظت وجود الدم في الإسهال يجب التوقف عن تناول هذا<br />الدواء و التحدث مع طبيبك فورا.<br /><strong>آثار جانبية غير شائعة (تؤثر على أكثر من 1 من كل 1000 شخص لكن أقل من 1 من كل<br />100 شخص):</strong><br />&bull;تفاعلات فرط التحسس )تشمل طفح الجلد الذي يكون أقل حدة من تفاعلات التحسس المذكورة في<br />الأعلى، طفح كتلي )شرى(، حكة(.<br />&bull;صداع.<br />&bull;تشوش الحس.<br />&bull;الشعور بالدوار.<br />&bull;رنين في الأذنين.<br />&bull;الشعور بالضعف و الشعور العام بالمرض.<br /><strong>آثار جانبية نادرة (تؤثر على أكثر من 1 من كل 10000 شخص لكن أقل من 1 من كل 1000<br />شخص):</strong><br />&bull;تغيرات في نتائج فحوصات الدم المتعلقة بصحة وظيفة الكبد.<br />&bull;فقر الدم.<br />&bull;انخفاض في عدد خلايا الدم )قد تتضمن الأعراض الشعور بالتعب، الإصابة بالتهابات جديدة،<br />التعرض للكدمات أوالنزيف بسهولة(.<br />&bull;زيادة عدد بعض أنواع خلايا الدم البيضاء.<br />&bull;زيادة عدد خلايا صغيرة ضرورية لتجلط الدم.<br />آثار جانبية نادرة جدا )تؤثر على أقل من 1 من كل 10000 شخص(:<br />&bull;تفاعلات فرط التحسس )مثل تشنج القصبات الهوائية، برفرية أو وذمة في الوجه والأطراف(.<br />&bull;قصور في وظيفة الكلى.<br />&bull;تلف في الكبد.<br />&bull;قد يؤدي تناول سيفبودوكسيم إلى زيادة فرصة الإصابة بالالتهابات الناتجة عن أنواع أخرى من<br />الكائنات الدقيقة بشكل مؤقت، مثلا، قد يحدث مرض القلاع.<br />&bull;أحد أنواع فقر الدم التي قد تكون حادة وينتج عن تحلل خلايا الدم الحمراء.<br /><strong>إذا ازدادت حدة أي من الآثار جانبية، أو إذا لاحظت حدوث أي آثار جانبية غير مذكورة في هذه<br />النشرة، الرجاء إخبار طبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيداً عن متناول و نظرهم.<br />لا تستخدم <strong>إيمدوكس&reg;&nbsp;</strong>المذكور على العلبة (EXP) معلق للشرب بعد تاريخ انتهاء الصلاحية&nbsp;<br />الخارجية والملصق. تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.<br /><strong>إيمدوكس&reg;</strong> معلق للشرب: يحفظ المسحوق الجاف بدرجة حرارة دون 30&nbsp;<br />بعد أن يتم خلط المسحوق مع الماء من قبل الصيدلي، احفظ زجاجة الدواء في الثلاجة.<br />بعد خلطه مع الماء,&nbsp;يمكن استعمال&nbsp;<strong>إيمدوكس&reg;&nbsp;</strong>معلق للشرب لمدة 14 يوما. يجب التخلص من<br />الدواء المتبقي بعد 14 يوما بالطريقة المناسبة.<br />يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل<br />الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير على<br />حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;تحتوي كل ملعقة 5 مل من المعلق على 100 ملغم من المادة الفعالة سيفبودوكسيم بروكسيتيل.<br />&bull;المكونات الأخرى هي هيدروكسي بروبيل سليلوز، ميكرو كريستالين سيليلوز، نشا الذرة،<br />سكروز، حامض الستريك، ثاني أكسيد السيليكون الغروي، مستحلب السيميثيكون، ميكروكريستالين<br />سيليلوز+ كاربوكسي ميثيل سليلوز، سكرين الصوديوم، صمغ الزنثان، بودرة بطعم الليمون، بودرة<br />بطعم الفانيلا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يبدو إيمدوكس&reg;&nbsp;معلق للشرب وما هي محتويات العلبة</strong><br /><strong>إيمدوكس&reg;</strong>&nbsp;معلق للشرب 100 ملغم/ 5 مل متوفر في زجاجات 50 مل، وتتوفر في العبوة مع ملعقة<br />قياس مدرجة (10 مل) وغطاء مقاوم للأطفال.<br />تحتوي الزجاجة على مسحوق يتم خلطه مع الماء المعقم من قبل الصيدلي، لتشكيل معلق بنكهة<br />الليمون جاهز للاستعمال.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>تصنيع</strong>: الشركة الدولية للدواء-الأردن<br /><strong>تعبئة: </strong>شركة مدينة الدواء للصناعات الدوائية - جدة - المملكة العربية السعودية.<br /><strong>مالك رخصة التسويق:</strong> مدينة الدواء للصناعات الدوائية &ndash; جدة - المملكة العربية السعودية.<br />هاتف: 00966126538171<br />فاكس: 00966126358138<br />الجوال: 00966540640627<br />madinet.aldawaa@gmail.com : البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emdox® 100 mg/5 ml Powder for Oral Suspension
Cefpodoxime proxetil 100 mg/5 ml Powder for Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5ml spoonful of liquid contains 100mg of the active substance cefpodoxime proxetil. For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Oral Suspension.
Emdox® Oral Suspension 100mg/5ml are available in 50ml bottles and come with a measuring spoon (10 ml) & a Child resistant cap.
The bottle contains powder which to be mixed with water by your pharmacist, to form a Lemon flavoured medicine ready for use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae, (excluding penicillin-resistant strains), Streptococcus pyogenes Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella)catarrhalis (including beta-lactamase producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes. NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis. Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae. Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains).<br />NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes. Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See DOSAGE AND ADMINISTRATION). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis. Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Staphylococcus saprophyticus. NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil&rsquo;s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>--</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefpodoxime proxetil is contraindicated in patients with a known allergy to cefpodoxime or to the cephalosporin group of antibiotics.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warnings: BEFORE THERAPY WITH CEFPODOXIME PROXETIL IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFPODOXIME, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF CEFPODOXIME IS TO BE ADMINISTERED TO PENICILLIN SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN ALLERGIC REACTION TO CEFPODOXIME PROXETIL OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.<br />Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cefpodoxime proxetil, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. A concerted effort to monitor for C. difficile in cefpodoxime-treated patients with diarrhea was undertaken because of an increased incidence of diarrhea associated with C. difficile in early trials in normal subjects. C. difficile organisms or toxin was reported in 10% of the cefpodoxime-treated adult patients with diarrhea; however, no specific diagnosis of pseudomembranous colitis was made in these patients. In post-marketing experience outside the United States, reports of pseudomembranous colitis associated with the use of cefpodoxime proxetil have been received. Precautions: General: In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of cefpodoxime proxetil should be reduced because high and prolonged serum antibiotic concentrations can occur in such individuals following usual doses. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics. (See DOSAGE AND ADMINISTRATION). As with other antibiotics, prolonged use of cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient&rsquo;s condition is essential. If superinfection occurs during therapy, appropriate measures should be taken. Prescribing cefpodoxime proxetil in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti-cholinergics (e.g., propantheline) delay peak plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC). Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels. Nephrotoxic drugs: Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential. Drug/Laboratory Test Interactions: Cephalosporins, including cefpodoxime proxetil, are known to occasionally induce a positive direct Coombs&rsquo; test.<br />Pediatric Use: Safety and efficacy in infants less than 2 months of age have not been established. Geriatric Use: Of the 3338 patients in multiple-dose clinical studies of cefpodoxime proxetil film-coated tablets, 521 (16%) were 65 and over, while 214 (6%) were 75 and over. No overall differences in effectiveness or safety were observed between the elderly and younger patients. In healthy geriatric subjects with normal renal function, cefpodoxime half-life in plasma averaged 4.2 hours and urinary recovery averaged 21% after a 400 mg dose was given every 12 hours for 15 days. Other pharmacokinetic parameters were unchanged relative to those observed in healthy younger subjects. Dose adjustment in elderly patients with normal renal function is not necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Teratogenic effects: Pregnancy Category B Cefpodoxime proxetil was neither teratogenic nor embryocidal when administered to rats during organogenesis at doses up to 100 mg/kg/day (2 times the human dose based on mg/m2) or to rabbits at doses up to 30 mg/kg/day (1 to 2 times the human dose based on mg/m2). There are, however, no adequate and well-controlled studies of cefpodoxime proxetil use in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Labor and Delivery: Cefpodoxime proxetil has not been studied for use during labor and delivery. Treatment should only be given if clearly needed. Nursing Mothers: Cefpodoxime is excreted in human milk. In a study of 3 lactating women, levels of cefpodoxime in human milk were 0%, 2% and 6% of concomitant serum levels at 4 hours following a 200 mg oral dose of cefpodoxime proxetil. At 6 hours post-dosing, levels were 0%, 9% and 16% of concomitant serum levels. Because of the potential for serious reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trials:<br />In clinical trials using multiple doses of cefpodoxime proxetil granules for oral suspension, 2128 pediatric patients (93% of whom were less than 12 years of age) were treated with the recommended dosages of cefpodoxime (10 mg/kg/day Q 24 hours or divided Q 12 hours to a maximum equivalent adult dose).<br />There were no deaths or permanent disabilities in any of the patients in these studies. Twenty-four patients (1.1%) discontinued medication due to adverse events thought possibly or probably related to study drug. Primarily, these discontinuations were for gastrointestinal disturbances, usually diarrhea, vomiting, or rashes.<br />Adverse events thought possibly or probably related, or of unknown relationship to cefpodoxime proxetil for oral suspension in multiple dose clinical trials (N=2128 patients treated with cefpodoxime) were:<br />Incidence Greater Than 1%:<br />Diarrhea 6%<br />The incidence of diarrhea in infants and toddlers (age 1 month to 2 years) was 12.8%.<br />Diaper rash/Fungal skin rash 2% (includes moniliasis)<br />The incidence of diaper rash in infants and toddlers was 8.5%.<br />Other skin rashes 1.8%<br />Vomiting 2.3%<br />Incidence Less Than 1%:<br />Body: Localized abdominal pain, abdominal cramp, headache, monilia, generalized abdominal pain, asthenia, fever, fungal infection.<br />Digestive: Nausea, monilia, anorexia, dry mouth, stomatitis, pseudomembranous colitis.<br />Hemic &amp; Lymphatic: Thrombocythemia, positive direct Coombs&rsquo; test, eosinophilia, leukocytosis, leukopenia, prolonged partial thromboplastin time, thrombocytopenic purpura. Metabolic &amp; Nutritional: Increased SGPT.<br />Musculo-Skeletal: Myalgia.<br />Nervous: Hallucination, hyperkinesia, nervousness, somnolence.<br />Respiratory: Epistaxis, rhinitis.<br />Skin: Skin moniliasis, urticaria, fungal dermatitis, acne, exfoliative dermatitis, maculopapular rash.<br />Special Senses: Taste perversion.<br />Laboratory Changes<br />Significant laboratory changes that have been reported in adult and pediatric patients in clinical trials of cefpodoxime proxetil, without regard to drug relationship, were: Hepatic: Transient increases in AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.<br />Hematologic: Eosinophilia, leukocytosis, lymphocytosis, granulocytosis, basophilia, monocytosis, thrombocytosis, decreased hemoglobin, decreased hematocrit, leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, thrombocythemia, positive Coombs&rsquo; test, and prolonged PT, and PTT.<br />Serum Chemistry: Hyperglycemia, hypoglycemia, hypoalbuminemia, hypoproteinemia, hyperkalemia, and hyponatremia.<br />Renal: Increases in BUN and creatinine.<br />Most of these abnormalities were transient and not clinically significant.<br />Post-marketing Experience:<br />The following serious adverse experiences have been reported: allergic reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme and serum sickness-like reactions, pseudomembranous colitis, bloody diarrhea with abdominal pain, ulcerative colitis, rectorrhagia with hypotension, anaphylactic shock, acute liver injury, in utero exposure with miscarriage, purpuric nephritis, pulmonary infiltrate with eosinophilia, and eyelid dermatitis.<br />One death was attributed to pseudomembranous colitis and disseminated intravascular coagulation.<br />Cephalosporin Class Labeling:<br />In addition to the adverse reactions listed above which have been observed in patients treated with cefpodoxime proxetil, the following adverse reactions and altered laboratory tests have been reported for cephalosporin class antibiotics:<br />Adverse Reactions and Abnormal Laboratory Tests: Renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, serum sickness-like reaction, hemorrhage, agranulocytosis, and pancytopenia.<br />Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. (See DOSAGE AND ADMINISTRATION and OVERDOSAGE.) If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p><p>For reporting side effects.</p><p>&nbsp;&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="width:444px"><tbody><tr><td style="width:440px">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Saudi Arabia:<br />&nbsp; &nbsp; &nbsp; &nbsp;- The National Pharmacovigilance and Drug Safety Center (NPC)<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Fax: +966-11-205-7662<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Toll free phone: 8002490000<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; E-mail: npc.drug@sfda.gov.sa<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; o Website: www.sfda.gov.sa/npc<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Other GCC States:<br />&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute rodent toxicity studies, a single 5 g/kg oral dose produced no adverse effects. In the event of serious toxic reaction from overdosage, hemodialysis or peritoneal dialysis may aid in the removal of cefpodoxime from the body, particularly if renal function is compromised. The toxic symptoms following an overdose of beta-lactam antibiotics may include nausea, vomiting, epigastric distress, and diarrhea.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cefpodoxime proxetil is an orally administered, extended spectrum, semi-synthetic antibiotic of the cephalosporin class. Microbiology: Mechanism of Action: Cefpodoxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefpodoxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Mechanism of Resistance: Resistance to Cefpodoxime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability. Cefpodoxime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the Indications and Usage (1) section:<br /> Saudi Arabia:<br />- The National Pharmacovigilance and Drug Safety Center (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br /> Other GCC States:<br />Please contact the relevant competent authority.<br />Gram-positive bacteria:<br />Staphylococcus aureus (methicillin-susceptible strains, including those producing penicillinases) Staphylococcus saprophyticus<br />Streptococcus pneumoniae (excluding penicillin-resistant isolates)<br />Streptococcus pyogenes<br />Gram-negative bacteria:<br />Escherichia coli<br />Klebsiella pneumoniae<br />Proteus mirabilis<br />Haemophilus influenzae (including beta-lactamase producing isolates)<br />Moraxella catarrhalis<br />Neisseria gonorrhoeae (including penicillinase-producing isolates)<br />The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for Cefpodoxime. However, the efficacy of Cefpodoxime in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials.<br />Gram-positive bacteria:<br />Streptococcus agalactiae<br />Streptococcus spp. (Groups C, F, G)<br />Gram-negative bacteria:<br />Citrobacter diversus<br />Klebsiella oxytoca<br />Proteus vulgaris<br />Providencia rettgeri<br />Haemophilus parainfluenzae<br />Anaerobic Gram-positive bacteria:<br />Peptostreptococcus magnus<br />Susceptibility Test Methods:<br />When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drug products used in resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.<br />Dilution techniques:<br />Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized test method 1,3. The MIC values should be interpreted according to criteria provided in Table 1.<br />Diffusion techniques:<br />Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds. The zone size should be determined using a standardized test method 2,3. This procedure uses paper disks impregnated with 10 mcg Cefpodoxime to test the susceptibility of microorganisms to Cefpodoxime. The disk diffusion interpretive criteria are provided in Table 1. Table 1. Susceptibility Test Interpretive Criteria for Cefpodoxime2.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p>Pathogen</p></td><td colspan="3"><p>Minimum Inhibitory Concentrations (mcg/mL)</p></td><td colspan="3"><p>Disk Diffusion Diameters (mm)</p></td></tr><tr><td><p>S</p></td><td><p>I</p></td><td><p>R</p></td><td><p>S</p></td><td><p>I</p></td><td><p>R</p></td></tr><tr><td><p>Enterobacteriaceae</p></td><td><p>&le; 2</p></td><td><p>4</p></td><td><p>&ge; 8</p></td><td><p>&ge; 21</p></td><td><p>18 to 20</p></td><td><p>&le; 17</p></td></tr><tr><td><p>Haemophilus influenzaea</p></td><td><p>&le; 2</p></td><td><p>-</p></td><td><p>&nbsp;</p></td><td><p>&ge; 21</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Streptococcus pneumoniae</p></td><td><p>&le; 0.5</p></td><td><p>1</p></td><td><p>&ge; 2</p><p>&nbsp;</p></td><td><p>-</p></td><td><p>-</p></td><td><p>-</p></td></tr><tr><td><p>Neisseria gonorrhoeaea</p></td><td><p>&le; 0.5</p></td><td><p>-</p></td><td><p>-</p></td><td><p>&nbsp;</p></td><td><p>-</p></td><td><p>-</p></td></tr></tbody></table><p>Susceptibility of staphylococci to Cefpodoxime may be deduced from testing only penicillin and either cefoxitin or oxacillin.<br />a = The current absence of resistant isolates precludes defining any results other than &ldquo;Susceptible.&rdquo; Isolates yielding MIC results other than &ldquo;Susceptible&rdquo; should be submitted to a reference laboratory for further testing.<br />A report of Susceptible indicates that the antimicrobial is likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentration at the infection site necessary to inhibit growth of the pathogen. A report of Intermediate indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the antimicrobial is not likely to inhibit growth of the pathogen if the antimicrobial compound reaches the concentrations usually achievable at the infection site; other therapy should be selected.<br />Quality Control:<br />Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individual performing the test1,2,3. Standard Cefpodoxime powder should provide the following range of MIC values noted in Table 2. For the diffusion technique using the 10 mcg disk, the criteria in Table 2 should be achieved.<br />Table 2. Acceptable Quality Control Ranges for Cefpodoxime</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>QC Strains</p></td><td style="vertical-align:top"><p>Minimum Inhibitory Concentrations (mcg/mL)</p></td><td style="vertical-align:top"><p>Disk Diffusion Zone diameters (mm)</p></td></tr><tr><td style="vertical-align:top"><p>Escherichia coli ATCC 25922</p></td><td><p>0.25 to 1</p></td><td><p>23 to 28</p></td></tr><tr><td style="vertical-align:top"><p>Haemophilus influenzae ATCC 49247</p></td><td><p>0.25 to 1</p></td><td><p>25 to 31</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pneumoniae ATCC 49619</p></td><td><p>0.03 to 0.12</p></td><td><p>28 to 34</p></td></tr><tr><td style="vertical-align:top"><p>Neisseria gonorrhoeae ATCC 49226</p></td><td><p>0.03 to 0.12</p></td><td><p>35 to 43</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus aureus ATCC 25923</p></td><td><p>---------</p></td><td><p>19 to 25</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus aureus ATCC 29213</p></td><td><p>1 to 8</p></td><td><p>---------</p></td></tr></tbody></table><p>ATCC&reg; is a registered trademark of the American Type Culture Collection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption and Excretion: Cefpodoxime proxetil is a prodrug that is absorbed from the gastrointestinal tract and de-esterified to its active metabolite, cefpodoxime. Following oral administration of 100 mg of cefpodoxime proxetil to fasting subjects, approximately 50% of the administered cefpodoxime dose was absorbed systemically. Over the recommended dosing range (100 to 400 mg), approximately 29 to 33% of the administered cefpodoxime dose was excreted unchanged in the urine in 12 hours. There is minimal metabolism of cefpodoxime in vivo. Effects of Food: When a 200 mg dose of the suspension was taken with food, the extent of absorption (mean AUC) and mean peak plasma concentration in fed subjects were not significantly different from fasted subjects, but the rate of absorption was slower with food (48% increase in Tmax). Pharmacokinetics of Cefpodoxime Proxetil Suspension: In adult subjects, a 100 mg dose of oral suspension produced an average peak cefpodoxime concentration of approximately 1.5 mcg/mL (range: 1.1 to 2.1 mcg/mL), which is equivalent to that reported following administration of the 100 mg tablet. Time to peak plasma concentration and area under the plasma concentration-time curve (AUC) for the oral suspension were also equivalent to those produced with film-coated tablets in adults following a 100 mg oral dose. The pharmacokinetics of cefpodoxime were investigated in 29 patients aged 1 to 17 years. Each patient received a single, oral, 5 mg/kg dose of cefpodoxime oral suspension. Plasma and urine samples were collected for 12 hours after dosing. The plasma levels reported from this study are as follows: CEFPODOXIME PLASMA LEVELS (mcg/mL) IN FASTED PATIENTS (1 to 17 YEARS OF AGE) AFTER SUSPENSION ADMINISTRATION</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top; width:131px"><p><strong>Dose (cefpodoxime equivalents) </strong></p></td><td colspan="7" style="width:355px"><p><strong>Time after oral ingestion</strong></p></td></tr><tr><td style="width:107px"><p><strong>1hr</strong></p></td><td><p><strong>2hr</strong></p></td><td><p><strong>3hr</strong></p></td><td><p><strong>4hr</strong></p></td><td><p><strong>6hr</strong></p></td><td><p><strong>8hr</strong></p></td><td><p><strong>12hr</strong></p></td></tr><tr><td style="vertical-align:top; width:131px"><p><strong>5 mg/kg1 </strong></p></td><td style="width:107px"><p><strong>1.4</strong></p></td><td><p><strong>2.1</strong></p></td><td><p><strong>2.1</strong></p></td><td><p><strong>1.7</strong></p></td><td><p><strong>0.9</strong></p></td><td><p><strong>0.4</strong></p></td><td><p><strong>0.09</strong></p></td></tr></tbody></table><p>1 Dose did not exceed 200 mg<br />Distribution:<br />Protein binding of cefpodoxime ranges from 22 to 33% in serum and from 21 to 29% in plasma. Skin Blister:<br />Following multiple-dose administration every 12 hours for 5 days of 200 mg or 400 mg cefpodoxime proxetil, the mean maximum cefpodoxime concentration in skin blister fluid averaged 1.6 and 2.8 mcg/mL, respectively. Skin blister fluid cefpodoxime levels at 12 hours after dosing averaged 0.2 and 0.4 mcg/mL for the 200 mg and 400 mg multiple-dose regimens, respectively.<br />Tonsil Tissue:<br />Following a single, oral 100 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in tonsil tissue averaged 0.24 mcg/g at 4 hours post-dosing and 0.09 mcg/g at 7 hours post-dosing. Equilibrium was achieved between plasma and tonsil tissue within 4 hours of dosing. No detection of cefpodoxime in tonsillar tissue was reported 12 hours after dosing. These results demonstrated that concentrations of cefpodoxime exceeded the MIC90of S. pyogenes for at least 7 hours after dosing of 100 mg of cefpodoxime proxetil.<br />Lung Tissue:<br />Following a single, oral 200 mg cefpodoxime proxetil film-coated tablet, the mean maximum cefpodoxime concentration in lung tissue averaged 0.63 mcg/g at 3 hours post-dosing, 0.52 mcg/g at 6 hours post-dosing, and 0.19 mcg/g at 12 hours post-dosing. The results of this study indicated that cefpodoxime penetrated into lung tissue and produced sustained drug concentrations for at least 12 hours after dosing at levels that exceeded the MIC90 for S. pneumoniae and H. influenzae.<br />CSF:<br />Adequate data on CSF levels of cefpodoxime are not available.<br />Effects of Decreased Renal Function:<br />Elimination of cefpodoxime is reduced in patients with moderate to severe renal impairment (&lt;50 mL/min creatinine clearance). (See PRECAUTIONS and DOSAGE AND ADMINISTRATION.) In subjects with mild impairment of renal function (50 to 80 mL/min creatinine clearance), the average plasma half-life of cefpodoxime was 3.5 hours. In subjects with moderate (30 to 49 mL/min creatinine clearance) or severe renal impairment (5 to 29 mL/min creatinine clearance), the half-life increased to 5.9 and 9.8 hours, respectively. Approximately 23% of the administered dose was cleared from the body during a standard 3-hour hemodialysis procedure.<br />Effect of Hepatic Impairment (cirrhosis):<br />Absorption was somewhat diminished and elimination unchanged in patients with cirrhosis. The mean cefpodoxime T1/2 and renal clearance in cirrhotic patients were similar to those derived in studies of healthy subjects. Ascites did not appear to affect values in cirrhotic subjects. No dosage adjustment is recommended in this patient population.<br />Pharmacokinetics in Elderly Subjects:<br />Elderly subjects do not require dosage adjustments unless they have diminished renal function. (See PRECAUTIONS.) In healthy geriatric subjects, cefpodoxime half-life in plasma averaged 4.2 hours (Vs 3.3 in younger subjects) and urinary recovery averaged 21% after a<br />400 mg dose was administered every 12 hours. Other pharmacokinetic parameters (Cmax, AUC, and Tmax) were unchanged relative to those observed in healthy young subjects.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>--</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxy propyl cellulose, microcrystalline cellulose, maize starch, sucrose, citric acid, colloidal silicon dioxide, simethicone emulsion, Microcrystalline cellulose and carboxymethyl cellulose, sodium saccharin, xanthan gum, lemon powder flavor, vanilla powder flavor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
The reconstituted suspension: can be stored for up to 14 days refrigerated (2- 8°C).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bottles: unreconstituted product should be stored below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Emdox&reg;</strong> Oral Suspension 100mg/5ml are available in 50ml bottles and come with a measuring spoon (10 ml) &amp; a Child resistant cap.<br />The bottle contains powder which to be mixed with water by your pharmacist, to form a Lemon flavoured medicine ready for use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed off in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Madinat Dawaa for pharmaceutical industries.
Jeddah-KSA
Tel: 00966126538171
Fax: 00966126358138
Mobile: 00966540640627
E-mail: madinet.aldawaa@gmail.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>